This included three drugs (Buparlisib, LJI308, and Pictilisib) targeting the PI3K/mTOR pathway, which has been identified as a potential drug target in osteosarcoma [4, 84], and consistent with this, patients with high TMEindex in this study did have higher activation of this pathway. This evidence concerns the gene MTOR and osteosarcoma.